SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689) (CBIO) — Jan 7, 2014

CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689)
Date: Jan. 7, 2014 · CIK: 0001253689 · Accession: 0001193125-14-004207

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-191567

Date
January 7, 2014
Author
Managing Director
Form
CORRESP
Company
CRESCENT BIOPHARMA, INC. (CBIO) (CIK 0001253689)

Letter

Re: GlycoMimetics, Inc. (the “Company”) – Request for Acceleration

Correspondence

January 7, 2014

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (File No. 333-191567)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as Representatives of the several underwriters of the Company’s proposed public offering of common shares, we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. Eastern Time on January 9, 2014, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the Act, we wish to advise you that we have distributed approximately 1,101 copies of the Company’s Preliminary Prospectus dated January 7, 2014 through the date hereof to underwriters, dealers, institutions and others.

We, the undersigned, as Representatives of the several underwriters, have complied and will continue to comply, and we have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.

[Signature Page Follows]

Very truly yours,
Jefferies LLC

Show Raw Text
CORRESP
1
filename1.htm

Correspondence

 January 7, 2014

 VIA EDGAR

 Securities and Exchange Commission

Division of Corporation Finance

 100 F Street,
N.E.

 Washington, D.C. 20549

Re:
GlycoMimetics, Inc. (the “Company”) – Request for Acceleration

Registration Statement on Form S-1 (File No. 333-191567)

 Ladies and Gentlemen:

 In accordance with Rule 461 under the Securities Act of 1933, as amended
(the “Act”), and as Representatives of the several underwriters of the Company’s proposed public offering of common shares, we hereby join the Company’s request for acceleration of the above-referenced Registration
Statement, as amended, requesting effectiveness for 4:00 p.m. Eastern Time on January 9, 2014, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the Act, we wish to advise you that we have distributed approximately 1,101 copies of the Company’s Preliminary Prospectus
dated January 7, 2014 through the date hereof to underwriters, dealers, institutions and others.

 We, the undersigned, as Representatives
of the several underwriters, have complied and will continue to comply, and we have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange
Act of 1934, as amended.

 [Signature Page Follows]

 Very truly yours,

Jefferies LLC

 Barclays Capital Inc.

 As Representatives of the several Underwriters

By:

Jefferies LLC

By:

/s/ Ashley Delp

Name:

Ashley Delp

Title:

Managing Director

By:

Barclays Capital Inc.

By:

/s/ Victoria Hale

Name:

Victoria Hale

Title:

Vice President